Cayman Elbasvir

Elbasvir is a direct-acting antiviral drug that potently inhibits hepatitis C virus (HCV) non-structural protein 5A (NS5A) with an EC₅₀ value of 2.2 pM in Huh7 human liver cancer cells expressing pH77S.3/GLuc2A, a cell-culture adapted HCV16 genotype 1a derivative and luciferase reporter, following a 48-hour exposure in vitro.^, NS5A is essential for HCV RNA synthesis and viral assembly, and elbasvir inhibits the assembly of new viral replicase complexes when used at a concentration of 50 pM. It exhibits potent inhibitory activity against a broad range of HCV genotypes with EC₅₀ values of 0.0002-34 nM in Huh7 cells expressing replicons of HCV genotype 4 NS5A and EC₅₀ values of less than 0.2 nM for replicons from all other tested genotypes except 2b.^,, Formulations containing elbasvir have been used alone and in combination with NS3/4A protease inhibitors in the treatment of HCV.

WARNING This product is not for human or veterinary use.